Results 51 to 60 of about 6,355,269 (225)

PPR56 target mutations opposite of P- and S-type PPRs.

open access: yes, 2023
Mutations have been introduced upstream of the two native PPR56 editing targets nad4eU272SL and nad3eU230SL in positions juxtaposed with P- and S-type PPRs assumed to follow the PPR-RNA code rules for amino acid positions 5 and L.
Jingchan Xie (16859288)   +5 more
core   +1 more source

There exists only one tumor necrosis factor

open access: yesМедицинская иммунология, 2021
Tumor necrosis factor (TNF) is an important proinflammatory and immunoregulatory cytokine with several unique protective and homeostatic functions. Since TNF is a mediator of several pathologies and is a part of “cytokine storm”, its significance for ...
S. A. Nedospasov
doaj   +1 more source

AI-powered therapeutic aptamer drug discovery: Targeting the CT-domain of CTGF for duchenne muscular dystrophy

open access: yesActa Pharmaceutica Sinica B
Duchenne muscular dystrophy (DMD), a fatal X-linked disorder, features progressive muscle fibrosis as a key driver of mortality. While CTGF represents a therapeutic target for DMD, its VWC-domain-targeting antibody (FG-3019) failed in clinical trials ...
Shanshan Yao   +18 more
doaj   +1 more source

Unidades de traducción culturalmente marcadas: propuesta de clasificación dinámica con fines traductológicos

open access: yesHermes, 2018
In the context of Translation Studies, this paper presents a proposal for classifying culturally marked translation units from a functional dynamic perspective that is considered to be more useful for both translation practice and translation-related ...
Inma Mendoza García
doaj   +1 more source

Legionella metaeffector exploits host proteasome to temporally regulate cognate effector. [PDF]

open access: yesPLoS Pathogens, 2010
Pathogen-associated secretion systems translocate numerous effector proteins into eukaryotic host cells to coordinate cellular processes important for infection.
Tomoko Kubori   +3 more
doaj   +1 more source

Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial

open access: yesRheumatology, 2018
Objectives Adherence to a treat to target (TTT) strategy is a recommended paradigm for RA; however, research shows there are many barriers to implementation.
Agnes Zak   +7 more
semanticscholar   +1 more source

Hypomorphic Mutations in the Central Fanconi Anemia Gene FANCD2 Sustain a Significant Group of FA-D2 Patients with Severe Phenotype. Running title : FA-D2 phenotype and FANCD2 mutations

open access: yes, 2007
Premi a l'excel·lència investigadora. Àmbit de les Ciències de la Salut. 2008FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a central role in DNA double-strand type damage responses.
Detlev Schindler   +52 more
core   +2 more sources

Semi-automatic parking slot marking recognition for intelligent parking assist systems

open access: yesThe Journal of Engineering, 2014
This paper proposes a semi-automatic parking slot marking-based target position designation method for parking assist systems in cases where the parking slot markings are of a rectangular type, and its efficient implementation for real-time operation ...
Ho Gi Jung
doaj   +1 more source

A Bayesian approach to targeted experiment design [PDF]

open access: yesBioinformatics, 2012
Abstract Motivation: Systems biology employs mathematical modelling to further our understanding of biochemical pathways. Since the amount of experimental data on which the models are parameterized is often limited, these models exhibit large uncertainty in both parameters and predictions.
Joep Vanlier   +3 more
openaire   +3 more sources

Aluminum-lithium target behavior

open access: yes, 1989
Information on physical properties and irradiation behavior of aluminum-lithium target alloys employed for the production of tritium in Savannah River reactors has been reviewed to support development of technology for the New Production Reactor (NPR ...
W.R. McDonell, McDonell, W.R.
core   +1 more source

Home - About - Disclaimer - Privacy